| BioWorld

Myriad's Stock Sale Gets $50.2M To Move Flurizan Through Clinic

Inhibitex Gains $35M After Dropping IPO Share Price

FDA Satisfied With Rat Data; Dyax Phase II Trials Resume

SeraCare Paying $14.3M To Buy Genomics Collaborative

CuraGen, TopoTarget Form HDAC Inhibitor Deal Worth Up To $100M

As it transforms itself from a genomics discovery company to a product development company, CuraGen Corp. in-licensed a promising cancer compound from the Danish firm TopoTarget A/S. (BioWorld Today) Read More

More Global Attendees Flock To Industry's Annual Meeting

BioWorld

June 7, 2004

Myriad's Stock Sale Gets $50.2M To Move Flurizan Through Clinic

Inhibitex Gains $35M After Dropping IPO Share Price

FDA Satisfied With Rat Data; Dyax Phase II Trials Resume

SeraCare Paying $14.3M To Buy Genomics Collaborative

Other News To Note

Correction

CuraGen, TopoTarget Form HDAC Inhibitor Deal Worth Up To $100M

More Global Attendees Flock To Industry's Annual Meeting

Today's news in brief

Today's news in brief

News in brief

BIO 2025: Makary lays out FDA’s path, launches pilot review program

New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema